Citigroup
KROS icon

Citigroup’s Keros Therapeutics KROS Stock Holding History

Citigroup’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$96.5K Buy
9,015
+6,807
+308% +$75.8K ﹤0.01% 4711
2026
Q1 		$24.4K Sell
2,208
-4,901
-69% -$75.7K ﹤0.01% 4769
2025
Q4 		$145K Buy
7,109
+4,192
+144% +$73.5K ﹤0.01% 4142
2025
Q3 		$46.1K Sell
2,917
-31,462
-92% -$465K ﹤0.01% 4528
2025
Q2 		$459K Sell
34,379
-37,378
-52% -$505K ﹤0.01% 3677
2025
Q1 		$731K Buy
71,757
+17,334
+32% +$201K ﹤0.01% 3458
2024
Q4 		$862K Buy
54,423
+31,042
+133% +$1.61M ﹤0.01% 3468
2024
Q3 		$1.36M Buy
23,381
+10,798
+86% +$533K ﹤0.01% 3002
2024
Q2 		$575K Sell
12,583
-104,873
-89% -$5.64M ﹤0.01% 3300
2024
Q1 		$7.78M Sell
117,456
-51,935
-31% -$3.08M 0.01% 1414
2023
Q4 		$6.73M Buy
169,391
+71,282
+73% +$2.24M ﹤0.01% 1418
2023
Q3 		$3.13M Sell
98,109
-54,738
-36% -$2.04M ﹤0.01% 1696
2023
Q2 		$6.14M Sell
152,847
-173,217
-53% -$7.59M ﹤0.01% 1376
2023
Q1 		$13.9M Sell
326,064
-86,039
-21% -$4.35M 0.01% 985
2022
Q4 		$19.8M Sell
412,103
-64,020
-13% -$2.99M 0.02% 802
2022
Q3 		$17.9M Buy
476,123
+13,753
+3% +$477K 0.01% 831
2022
Q2 		$12.8M Buy
462,370
+454,498
+5,774% +$19.9M 0.01% 1034
2022
Q1 		$428K Sell
7,872
-24,248
-75% -$1.24M ﹤0.01% 3617
2021
Q4 		$1.88M Buy
32,120
+13,518
+73% +$674K ﹤0.01% 2677
2021
Q3 		$736K Sell
18,602
-22,942
-55% -$816K ﹤0.01% 3329
2021
Q2 		$1.76M Sell
41,544
-1,153
-3% -$62.5K ﹤0.01% 2755
2021
Q1 		$2.63M Buy
42,697
+39,391
+1,192% +$2.5M ﹤0.01% 2304
2020
Q4 		$233K Buy
3,306
+2,971
+887% +$187K ﹤0.01% 4877
2020
Q3 		$13K Sell
335
-608
-64% -$24.1K ﹤0.01% 6452
2020
Q2 		$35K Buy
+943
New +$29.1K ﹤0.01% 6227

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Citigroup's KROS Position: Q2 2026 in Review

Citigroup increased its Keros Therapeutics (KROS) stake by 308% in Q2 2026, buying an estimated $75.8K and bringing the position to 9,015 shares worth $96.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4711.

Citigroup first reported a position in KROS in Q2 2020 and has held it in 25 quarters since. The position peaked at $19.8M in Q4 2022. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Citigroup held 9,015 shares of Keros Therapeutics worth $96.5K as of Q2 2026.
  • Citigroup bought 6,807 Keros Therapeutics shares in Q2 2026, an estimated $75.8K.
  • Keros Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #4711 holding.
  • Citigroup first reported a position in Keros Therapeutics in Q2 2020 and has held it in 25 quarters since.
  • Citigroup's Keros Therapeutics position peaked at $19.8M in Q4 2022.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.